The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 2, 2006, Pages 169-175

  Nieto, Jose M ^a,b   Pisegna, Joseph R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Esomeprazole; Gastric acid hypersecretion; Gastrinoma; Lansoprazole; Multiple endocrine neoplasia type 1; Omeprazole; Pancreatic tumour; Pantoprazole; Peptic ulcer disease; Proton pump inhibitors; Rabreprazole; Zollinger Ellison syndrome

Indexed keywords

CALCIUM; CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PENTAGASTRIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SECRETIN;

CLINICAL TRIAL; CONTROL; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG STABILITY; GASTRIN BLOOD LEVEL; GASTRIN CELL; HUMAN; INCIDENCE; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; PATHOPHYSIOLOGY; PEPTIC ULCER; PH; REVIEW; STOMACH ACID SECRETION; STOMACH CARCINOID; STOMACH TUMOR; TACHYPHYLAXIS; TUMOR LOCALIZATION; UNITED STATES; ZOLLINGER ELLISON SYNDROME;

ANTI-ULCER AGENTS; HUMANS; PROTON PUMPS; ZOLLINGER-ELLISON SYNDROME;

EID: 33144455214     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.2.169     Document Type: Review

References (34)

1. ZOLLINGER RM, ELLISON EH: Primary peptic ulceration of the jejunum associated with islet cell tumors of the pancreas. Ann. Surg. (1955) 142(4):709-722.
2. ISENBERG JI, WALSH JH, GROSSMAN MI: Zollinger Ellison syndrome. Gastroenterology (1973) 65(1):140-165.
3. STAGE JG, STADIL F: The clinical diagnosis of the Zollinger-Ellison syndrome. Scand. J. Gastroenterol. (1979) 53:79-91.
4. CORLETO VD, ANNIBALE B GIBRIL F et al.: Does the widespread use of proton pump inhibitors mask, complicate, and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment. Pharmacol. Ther. (2001) 15(10):1555-1561.
5. ZHUANG Z, VORTMEYER AO, PACK S et al.: Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. (1997) 57(21):4682-4686.
6. YALOW RS, BERSON SA: Radioimmunoassay of gastrin. Gastroenterology (1970) 58(1):1-14.
7. HAVU N: Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion (1986) 35(1):42-55.
8. LI H, HELANDER HF: Hypergastrinemia increases proliferation of gastroduodenal epithelium during gastric ulcer healing in rats. Dig. Dis. Sci. (1996) 41(1):40-48.
9. SHIMODA SS, SAUNDERS DR, RUBIN CE: The Zollinger Ellison syndrome with steatorrhea. II. The mechanism of fat and vitamin B12 malabsorption. Gastroenterology (1968) 55(6):705-723.
10. HIRSCHOWITZ BI: Gastric secretion of acid and pepsin in patients with esophageal stricture and appropriate controls. Dig. Dis. Sci. (1996) 41(11):2115-2122.
11. YU F, VENZON DJ, SERRANO J et al.: Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer (1999) 85(7):1470-1483.
12. DEVENEY CW, EVENEY KS, JAFFE BM et al.: Use of calcium and secretin in the diagnosis of gastrinoma. Ann. Int. Med. (1977) 87(6):680-686.
13. IMAMURA M, TAKAHASHI K: Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. World J. Surg. (1993) 17(4):433-438.
14. VADA M, KOMOTO L, DOI R et al.: Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. World J. Surg. (2002) 26(10):1291-1296.
15. TERMANINI B, GIBRIL F, STEWART CA et al.: A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment. Pharmacol. Ther. (1996) 10(1):61-71.
16. STEWART CA TERMANINI B, SUTLIFF VE et al.: Management of the Zollinger-Ellison syndrome in pregnancy. Am. J. Obstet. Gynecol. (1997) 176(1):224-233.
17. LEW EA, PISEGNA JR, STARR JA et al.: Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology (2000) 118(4):696-704.
18. RICHARDSON CT, WALSH JH: The value of a histamine H2-receptor antagonist in the management of patients with the Zollinger-Ellison syndrome. N. Engl. J. Med. (1976) 294(3):133-135.
19. ROY PK, VENZON DJ, FEIGENBAUM KM et al.: Gastric acid secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent, and role in diagnosis- a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (2001) 80(3):189-222.
20. WILSON SD, ELLISON EH: Survival in patients with the Zollinger-Ellison syndrome treated by total gastrectomy. Am. J. Surg. (1966) 111(6):787-791.
21. STRADER DB, BENJAMIN SB, ORBUCH M et al.: Esophageal function and occurrence of Barrett's esophagus in Zollinger-Ellison syndrome. Digestion (1995) 56(5):347-356.
22. CARSWELL CI, GOA KL: Rabeprazole: an update of its use in acid-related disorders. Drugs (2001) 61(15):2327-2356.
23. METZ DC, SOFFER E, FORSMARK CE et al.: Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am. J. Gastroenterol. (2003) 98(2):301-307.
24. METZ DC, PISEGNA JR, RINGHAM GL et al.: Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig. Dis. Sci. (1993) 38(2):245-256.
25. HIRSCHOWITZ BI, SIMMONS J, MOHNEN J: Clinical outcome using lansoprazole in acid hypersecretors with nd without Zollinger-Ellison syndrome: a 13-year prospective study. Clin. Gastroenterol. Hepatol. (2005) 3(1):39-48.
26. KOVACS TO, LEE CQ, CHIU YL et al.: Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. Aliment. Pharmacol. Ther. (2004) 20(8):883-889.
27. CHEN CY, LU CL, LUO JC et al.: Esomeprazole tablet versus omeprazole capsule in treating erosive esophagitis. World J. Gastroenterol. (2005) 11(20):3112-3117.
28. METZ DC, PISEGNA JR, FISHBEYN VA et al.: Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology (1992) 103(5):1498-1508.
29. HOWARD JM, CHREMOS AN et al.: Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology (1985) 88(4):1026-1033.
30. COLLEN MJ, HOWARD JM, MCARTHUR KE et al.: Comparison of the effectiveness of ranitidine and cimetidine in the treatment of gastric hypersecretion. Ann. Int. Med. (1984) 100(1):52-58.
31. TAKEUCHI K, KAJIMURA M, KODAIRA M et al.: Up-regulation of H2 receptor and adenylate cyclase in rabbit parietal cells during prolonged treatment with H2-receptor antagonists. Dig. Dis. Sci. (1999) 44(8):1703-1709.
32. DANIELS IR: Omeprazole, its isomers, and the carcinoid question. Lancet (2001) 357(9264):1290-1291.
33. SUZUKI H, HIBI T: Novel effects other than antisecretory action and off-label use of proton pump inhibitors. Expert Opin. Pharmacother. (2005) 6(1):59-67.
34. FISHBEYN VA, NORTON JA, BENYA RV et al.: Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann. Intern. Med. (1993) 119:199-206.